Literature DB >> 33965595

Prevalence of Bronchiectasis in Patients with Chronic Rhinosinusitis in a Tertiary Care Center.

Anju T Peters1, Sumit Bose2, Amina Guo2, Newton Li2, Mariel Benjamin2, Michelle Prickett3, Raul S Villareal2, Amy Yang4, Atsushi Kato2, Robert C Kern5, Bruce K Tan5, Leslie C Grammer2, Robert P Schleimer5, David B Conley6, Stephanie S Smith6, Kevin C Welch6, Whitney W Stevens5.   

Abstract

BACKGROUND: Whereas chronic rhinosinusitis (CRS) is associated with asthma, and vice versa, the association between CRS and other lower respiratory conditions is not well-established. Bronchiectasis is characterized by permanent damage of the airways, and as many as 45% of bronchiectasis patients have CRS, but the prevalence of bronchiectasis among CRS patients is not known.
OBJECTIVE: To determine the prevalence of bronchiectasis among CRS patients and to characterize demographic and clinical features of patients with bronchiectasis and CRS.
METHODS: Electronic medical records of patients with rhinosinusitis were searched by computer algorithm supplemented with manual chart review to identify patients with CRS, asthma, and/or bronchiectasis. Demographic and clinical features and antibiotic courses for sinopulmonary infections 2 years before and after sinus surgery were obtained by manual chart review.
RESULTS: The prevalence of bronchiectasis as determined by International Classification of Diseases, Ninth Revision code was significantly higher in CRS patients than in asthmatic patients (2.3% vs 1.7%; P < .003). Similarly, based on a text word search of "bronchiectasis" in the chest computed tomography (CT) scan reports, patients with CRS who had chest CT scans had a higher prevalence of bronchiectasis than did asthmatic patients with chest CT scans (24.3% vs 19.5%; P = .005). Patients with CRS and concurrent bronchiectasis did not have a reduction in the frequency of sinopulmonary infections after sinus surgery compared with patients with CRS without bronchiectasis (P < .05).
CONCLUSIONS: Bronchiectasis is an important comorbidity in patients with CRS and may identify a severe phenotype of chronic sinonasal disease.
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; Asthma; Bronchiectasis; CRSsNP; CRSwNP; Chronic rhinosinusitis; Nasal polyp; Prevalence

Mesh:

Year:  2021        PMID: 33965595     DOI: 10.1016/j.jaip.2021.04.054

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  5 in total

1.  Strong and consistent associations of precedent chronic rhinosinusitis with risk of non-cystic fibrosis bronchiectasis.

Authors:  Brian S Schwartz; Saba A Al-Sayouri; Jonathan S Pollak; Annemarie G Hirsch; Robert Kern; Bruce Tan; Atsushi Kato; Robert P Schleimer; Anju T Peters
Journal:  J Allergy Clin Immunol       Date:  2022-03-18       Impact factor: 14.290

2.  CRS-PRO and SNOT-22 correlations with type 2 inflammatory mediators in chronic rhinosinusitis.

Authors:  Samuel D Racette; Alexander L Schneider; Meera Ganesh; Julia H Huang; David S Lehmann; Caroline P E Price; Samuel G Rodegherio; Abhita T Reddy; Jacob G Eide; David B Conley; Kevin C Welch; Robert C Kern; Stephanie Shintani-Smith; Atsushi Kato; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2022-04-01       Impact factor: 5.426

3.  Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study.

Authors:  Claudia Crimi; Raffaele Campisi; Santi Nolasco; Sebastian Ferri; Giulia Cacopardo; Pietro Impellizzeri; Maria Provvidenza Pistorio; Evelina Fagone; Corrado Pelaia; Enrico Heffler; Nunzio Crimi
Journal:  J Asthma Allergy       Date:  2021-11-30

4.  The relative proportion of comorbidities among rhinitis and rhinosinusitis patients and their impact on visit burden.

Authors:  Mikko Nuutinen; Annina Lyly; Paula Virkkula; Maija Hytönen; Elmo Saarentaus; Antti Mäkitie; Aarno Palotie; Paulus Torkki; Jari Haukka; Sanna Toppila-Salmi
Journal:  Clin Transl Allergy       Date:  2022-07-21       Impact factor: 5.657

Review 5.  Biological Therapy of Severe Asthma and Nasal Polyps.

Authors:  Agamemnon Bakakos; Florence Schleich; Petros Bakakos
Journal:  J Pers Med       Date:  2022-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.